Replies to post #111484 on Biotech Values

[microcapfun]

>>INCY’s drug might be able to show statsig non-inferiority, which ought to be good enough for FDA approval with a suitable SPA.<<

Thanks, Dew. Do you think that's likely given the following?

Drug ACR20 minus placebo ACR20:

Pfizer: 39%
Incyte: 20%

Reminder: The ACR20 drug/placebo comparison was Incyte's primary Phase 2B endpoint.

micro